The synthetic oleanane triterpenoid CDDO is a Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. CDDO-TFEA is a trifluoroethylamide derivative of CDDO with enhanced ability to cross the blood brain barrier. It has been shown to enhance Nrf2 expression and signaling in various models of neurodegeneration, including those that simulate multiple sclerosis, amyotrophic lateral sclerosis, and Huntington’s disease. CDDO-TFEA induces apoptosis of Ewing’s sarcoma and neuroblastoma cell lines, preventing colony formation at IC50 values ranging from 85-170 nM.
CDDO-TFEA (RTA 404; TP-500) is a trifluoroacetamide derivative of CDDO with enhanced ability to cross the blood-brain barrier. CDDO is an Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. CDDO-TFEA can enhance Nrf2 expression and signaling in various neurodegenerative disease models, including those mimicking multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. CDDO-TFEA induces apoptosis and blocks colony formation in Ewing's sarcoma and neuroblastoma cell lines with IC50 values ranging from 85-170 nM.
[1]. pareek tk, belkadi a, kesavapany s, et al. triterpenoid modulation of il-17 and nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. sci rep. 2011;1:201.
[2]. neymotin a, calingasan ny, wille e, et al. neuroprotective effect of nrf2/are activators, cddo ethylamide and cddo trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. free radic biol med. 2011 jul 1;51(1):88-96.
[3]. stack c, ho d, wille e, et al. triterpenoids cddo-ethyl amide and cddo-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of huntington's disease. free radic biol med. 2010 jul 15;49(2):147-58.
